Dehydration News and Research

Latest Dehydration News and Research

Sport Endurance develops new formula that enables safe consumption of Creatine

Sport Endurance, Inc, a health supplement company, has developed a revolutionary formula that enables the safe consumption of Creatine, a proven muscle-building and performance enhancing dietary supplement.

17 Aug 2010

Amgen reports top-line results from Vectibix Phase 3 trial for head and neck cancer

Amgen today announced top-line results from a randomized Phase 3 trial evaluating Vectibix as a first-line treatment in patients with recurrent and/or metastatic squamous cell head and neck cancer. The data showed the addition of Vectibix to platinum-based chemotherapy did not result in a statistically significant improvement in overall survival, the primary endpoint, compared to chemotherapy alone.

12 Aug 2010

First Salmonella lawsuit filed against Yum Brands

The first Salmonella lawsuit has been filed in the pair of Salmonella outbreaks that has sickened 155 people in 21 states. The lawsuit was filed against Yum! Brands (the parent company of Taco Bell) in the Commonwealth of Kentucky, Franklin County Circuit Court. The lawsuit was filed on behalf of a Scott county resident by food safety law firm Marler Clark.

7 Aug 2010

Project for improving nurses' assessment skills to detect and alleviate delirium symptoms

In the future, nurses may more accurately detect and alleviate symptoms of delirium in persons with dementia, thanks to a five-year, $2.7-million grant from the National Institute of Nursing Research.The project, led by Donna Fick, professor of nursing, Penn State, seeks to improve nurses' assessment skills and reduce the use of drugs to treat delirium and dementia.

5 Aug 2010

Consumers who have MMS should stop using it immediately, FDA warns

The U.S. Food and Drug Administration is warning consumers not to take Miracle Mineral Solution, an oral liquid solution also known as "Miracle Mineral Supplement" or "MMS." The product, when used as directed, produces an industrial bleach that can cause serious harm to health.

31 Jul 2010

$Pivotal PINNACLE trial results of VELCADE in patients with relapsed/refractory MCL released$

Pivotal PINNACLE trial results of VELCADE in patients with relapsed/refractory MCL released

Millennium: The Takeda Oncology Company today reported new correlative science data from the pivotal PINNACLE trial of VELCADE (bortezomib) in patients with relapsed/refractory mantle cell lymphoma. The data, derived from an analysis of archived tumor samples, tested pre-specified biomarkers for their association with time to progression and response to treatment with VELCADE in patients with relapsed MCL.

30 Jul 2010

Researchers unveil mechanism of cholera bacteria to create cell energy

Researchers have found that an enzyme in the bacteria that causes cholera uses a previously unknown mechanism in providing the bacteria with energy. Because the enzyme is not found in most other organisms, including humans, the finding offers insights into how drugs might be created to kill the bacteria without harming humans.

29 Jul 2010

Allos reports topline results from Phase 2b trial of FOLOTYN vs erlotinib in advanced NSCLC

Allos Therapeutics, Inc. today announced topline results from the Company's randomized Phase 2b investigational trial of FOLOTYN® (pralatrexate injection) versus erlotinib in patients with Stage IIIB/IV (advanced) non-small cell lung cancer (NSCLC) who had received one or two prior systemic treatments including at least one prior platinum-based regimen. The objective of the trial was to estimate the efficacy of FOLOTYN compared to that of erlotinib as assessed by overall survival.

28 Jul 2010

Allos reports net loss of $20.0 million for second-quarter 2010

Allos Therapeutics, Inc. today reported its financial results and business highlights for the quarter and six months ended June 30, 2010.

28 Jul 2010

NPS completes patient randomization in GATTEX Phase 3 study for PN dependent short bowel syndrome

NPS Pharmaceuticals, a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced the completion of patient randomization in its Phase 3 registration study of GATTEX® (teduglutide). The double-blind, placebo-controlled safety and efficacy study, which is known as STEPS, is being conducted in patients with parenteral nutrition (PN) dependent short bowel syndrome (SBS) and is now fully randomized with 86 patients.

23 Jul 2010

Iced tea increases risk of kidney stone formation and surgery

Unfortunately, for health reasons, Mulac has been forced to go cold turkey. All the iced tea he was downing helped to bring on an excruciating bout of kidney stones that eventually led to surgery at Loyola University Hospital in Maywood, Ill.

21 Jul 2010

Genentech disappointed with FDA ODAC's recommendation against Avastin

Genentech, Inc., a member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 12 to one that use of Avastin® (bevacizumab) in combination with paclitaxel for previously untreated (first-line) advanced HER2-negative breast cancer be removed from Avastin's U.S. label.

21 Jul 2010

Lots of water breaks prevent dehydration in kids

Scorching heat has taken its toll across the country this summer with record temperatures and heat indexes reaching well above 100 degrees. Add kids playing outside and outdoor summer activities in full swing to the dangerous heat you've got a hazardous combination.

20 Jul 2010

An overview of heart palpitations from Mayo Clinic

Almost everyone feels occasional heart palpitations -- a change in the heart's rhythm. Palpitations range from what feels like a skip, flip or bump in the heart's rhythm to a sustained, racing heartbeat.

16 Jul 2010

Type 1 diabetes affects athletic performance, new study finds

A new study led by York University researchers finds that young athletes with Type 1 diabetes may experience a marked decrease in performance as a result of their blood sugar levels.

15 Jul 2010

Strativa receives FDA approval for Zuplenz oral soluble film

Strativa Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has approved Zuplenz® (ondansetron) oral soluble film for the prevention of postoperative, highly and moderately emetogenic cancer chemotherapy-induced, and radiotherapy-induced nausea and vomiting. Zuplenz, a unique formulation of ondansetron, is the first oral soluble film approved by the FDA as a prescription medication.

3 Jul 2010

Afinitor more than doubles progression-free survival in advanced pancreatic NET: Study

Novartis Pharmaceuticals Corporation announced today that results of a Phase III study show Afinitor® (everolimus) tablets plus best supportive care (BSC) more than doubled progression-free survival, or time without tumor growth, versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (NET). The study, RADIANT-3, was presented at the 12th World Congress on Gastrointestinal Cancer and is part of the largest clinical trial program in patients with advanced NET.

1 Jul 2010

Tranzyme reports positive results from TZP-102 Phase 2 study in diabetic patients with gastroparesis

Tranzyme Pharma announced positive top-line results today from a Phase 2, double-blind, placebo-controlled study evaluating TZP-102 capsules in diabetic patients with gastroparesis, a serious disorder characterized by the inability of the stomach to empty food efficiently. The study achieved a clinically meaningful and statistically significant improvement in critical gastroparesis-related symptoms. All three TZP-102 doses tested were effective, safe and well tolerated.

29 Jun 2010

JANUMET results in greater blood sugar reductions in patients with type 2 diabetes compared to pioglitazone

New data were presented at the American Diabetes Association 70th Annual Scientific Sessions from a study comparing JANUMET (sitagliptin/metformin) to pioglitazone. In this study, JANUMET resulted in significantly greater blood sugar reductions in patients with type 2 diabetes compared with pioglitazone.

28 Jun 2010

CHMP adopts positive opinion on pending MAA for SYCREST sublingual tablets

Merck announced that the Committee for Medicinal Products for Human Use adopted a positive opinion on the pending Marketing Authorization Application for SYCREST (asenapine) sublingual tablets. The CHMP has recommended that the European Commission grant a marketing authorization for SYCREST for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults. The CHMP did not support an indication for the treatment of schizophrenia.

25 Jun 2010

Dehydration News and Research

Latest Dehydration News and Research

Sport Endurance develops new formula that enables safe consumption of Creatine

Amgen reports top-line results from Vectibix Phase 3 trial for head and neck cancer

First Salmonella lawsuit filed against Yum Brands

Project for improving nurses' assessment skills to detect and alleviate delirium symptoms

Consumers who have MMS should stop using it immediately, FDA warns

Pivotal PINNACLE trial results of VELCADE in patients with relapsed/refractory MCL released

Researchers unveil mechanism of cholera bacteria to create cell energy

Allos reports topline results from Phase 2b trial of FOLOTYN vs erlotinib in advanced NSCLC

Allos reports net loss of $20.0 million for second-quarter 2010

NPS completes patient randomization in GATTEX Phase 3 study for PN dependent short bowel syndrome

Iced tea increases risk of kidney stone formation and surgery

Genentech disappointed with FDA ODAC's recommendation against Avastin

Lots of water breaks prevent dehydration in kids

An overview of heart palpitations from Mayo Clinic

Type 1 diabetes affects athletic performance, new study finds

Strativa receives FDA approval for Zuplenz oral soluble film

Afinitor more than doubles progression-free survival in advanced pancreatic NET: Study

Tranzyme reports positive results from TZP-102 Phase 2 study in diabetic patients with gastroparesis

JANUMET results in greater blood sugar reductions in patients with type 2 diabetes compared to pioglitazone

CHMP adopts positive opinion on pending MAA for SYCREST sublingual tablets

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

The evolution of OCT for retinal imaging and disease intervention

Dehydration News and Research

Latest Dehydration News and Research

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

The evolution of OCT for retinal imaging and disease intervention

Newsletters you may be interested in